TRPV1 and ischemia: Our hypothesis was that treatment with CS would activate TRPV1 in the heart under conditions of ischemia and reperfusion, restoring control of Ca2+ flow into cells and elevating the bioavailability of NO, thereby reducing ROS and enhancing the cardioprotective mechanisms.